share_log

Biodexa Announces $7M Of Gross Proceeds From Warrant Exercises And An Agreement Between The Company And Several Accredited Investors To Exercise Certain Existing Series E Warrants And Series F Warrants To Purchase Up To An Aggregate Of 4,358,322 ADSs

Benzinga ·  May 22 20:33

Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises

Proceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking Twice that Amount in Non-dilutive Grant Funding

Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces $7 million of gross proceeds from the exercise of previously issued warrants and an agreement between the Company and several accredited investors to exercise certain existing Series E warrants ("Series E Warrants") and Series F warrants ("Series F Warrants," and together with the Series E Warrants, the "Existing Warrants") to purchase up to an aggregate of 4,358,322 of the Company's American Depositary Shares ("ADSs) (each ADS represents 400 ordinary shares, nominal value £0.001 of the Company ("Ordinary Shares")).

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment